Dabrafenib plus trametinib achieves good overall and progression-free survival in BRAF inhibitor-naïve patients with BRAF V600 mutation-positive metastatic melanoma, a study published online ahead of print in the Journal of Clinical Oncology has shown.1
Scientific Publications
ASCO: Immunotherapy is ‘Cancer Advance of the Year’
ASCO has named progress in immunotherapy for melanoma and other malignancies as the top cancer advance of the year, according to “Clinical Cancer Advances 2016: ASCO’s Annual Report on Progress Against Cancer.”
Using Mouse Avatars Aids Identification of Effective Targeted Therapies for Patients With Melanoma
Using xenograft mice as avatars of patients with melanoma, scientists demonstrated that a previously ineffective targeted drug may be quite potent in halting disease progression in certain patients. Their findings were published in Clinical Cancer Research (doi:10.1158/1078-0432.CCR-15-1762).
Scientific Journals for January 2016
Ophthalmology BAP1 Germline Mutations in Finnish Patients with Uveal Melanoma Presented at: European Association for Vision and Eye Research Annual Meeting October 2014, Nice, France; and International Society of Ocular Oncology…
Read More